Search Results

Inari Medical’s FlowTriever Evaluated in Interim Data From FLASH Registry of Pulmonary Embolism Patients

October 28, 2021—Inari Medical, Inc. announced positive acute and long-term interim results from the first 500 pulmonary embolism (PE) patients enrolled in FLASH, the FlowTriever Outcomes Registry.

Jupiter’s Vertex PE System Evaluated in SPIRARE II Pivotal Trial

May 26, 2026—Jupiter Endovascular announced results from the SPIRARE II pivotal trial of the company’s Vertex pulmonary embolectomy system in the treatment of patients with acute, intermediate-risk pulmonary embolism (PE).

FLASH Registry Assesses Inari’s FlowTriever Mechanical Thrombectomy System for Acute PE

September 18, 2022—Clinical outcomes were presented for the complete nationwide cohort of FLASH, the FlowTriever All-Comer Registry for Patient Safety and Hemodynamics.

SPIRARE II Pivotal Trial of Jupiter’s Vertex Pulmonary Embolectomy System Completes Enrollment

February 5, 2026—Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the company’s Vertex pulmonary embolectomy system in patients with acute, intermediate-risk pulmonary embolism (PE).

United States Arm of ALIVE Study Begins for BioVentrix Revivent TC System

October 4, 2017—BioVentrix, Inc. announced enrollment of the first patient in the United States arm of the ALIVE pivotal clinical trial.

Jupiter Endovascular Receives IDE Approval for SPIRARE II Pivotal Trial

September 10, 2024—Jupiter Endovascular, Inc., announced recently that the FDA has approved the company’s application for an investigational device exemption (IDE) for the SPIRARE II pivotal study in the United States.